We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (PePiTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00994864
Recruitment Status : Unknown
Verified November 2018 by Jules Bordet Institute.
Recruitment status was:  Active, not recruiting
First Posted : October 14, 2009
Last Update Posted : November 29, 2018
Information provided by (Responsible Party):
Jules Bordet Institute

Brief Summary:
The primary working hypothesis is that preoperative chemo-sensitivity testing using fluorodeoxyglucose positron emission tomography (FDG-PET) performed before and after one course of FOLFOX (folinic acid, fluorouracil, oxaliplatin) can identify the patients that will least likely have a significant benefit from adjuvant FOLFOX for stage III colon cancer. The benefit will be analyzed by correlating the preoperative FDG-PET uptake changes to the disease free and overall survival.

Condition or disease Intervention/treatment Phase
Colon Cancer Drug: FOLFOX Not Applicable

Detailed Description:

Patients with histological confirmed colon adenocarcinoma compatible with clinical stage II or III are eligible for study screening. Receipt of a signed informed consent and study inclusion should be done within 15 days after histological diagnosis. A usual workup for preoperative staging of colon cancer must be done not more than 1 month before study inclusion and include CEA assessment, positive histological sample for colon adenocarcinoma and chest and abdominal CT scan. After receipt of the written consent, the patient undergoes baseline PET/CT scan and donates blood samples for CTC and SNP analyses. Delay between baseline examinations and histological diagnosis must not exceed 21 days. The baseline examinations should be done within 1 week before beginning of the first course of FOLFOX chemotherapy. Thirteen to 15 days after chemotherapy, the PET/CT and blood sampling for CTC analysis are repeated. Standard surgery follows after 15 days but no more than 30 days from Day 1 of preoperative chemotherapy. Two frozen tissue cores are obtained during surgery and sent immediately in dry ice shipping to the central Tumour Bank (Jules Bordet Institute) or stored locally at -80°C to be sent in batches to the central tumour bank. Thereafter, the patient receives standard care, according to tumour pathological stage. In fully eligible patients, FOLFOX chemotherapy should be started not more than 45 days after surgery. In stage III patients otherwise ineligible, recommendation is to start FOLFOX chemotherapy within 45 days after surgery although such patients will not be included in the primary analysis. Treatment in case of stage II or stage IV colon cancer is left at investigator's discretion. Eleven courses of adjuvant FOLFOX are foreseen, in order to match the usual recommendation coming from the Mosaic Trial.

Follow-up procedures after completion of adjuvant treatment will follow standard European clinical recommendations for stage II and III patients. Clinical follow-up data will be obtained for all patients, including those with stage II disease, with a minimum follow-up time of three years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 235 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Study Start Date : November 2009
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Arm Intervention/treatment
adjuvant FOLFOX (1 pre-operative cycle)
One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Other Name: FOLFOX-4 or equivalent

Primary Outcome Measures :
  1. Examine the predictive value of PET-assessed tumour FDG uptake response after one course of preoperative chemotherapy on the outcome of adjuvant therapy, measured by 3-year DFS. [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]

Secondary Outcome Measures :
  1. Examine the predictive value of PET-assessed tumour FDG uptake changes after one course of preoperative chemotherapy on OS [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  2. Evaluate the best cut-off value for relative delta SUV in assessment of preoperative chemotherapy response by FDG-PET/CT imaging. [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  3. Analyze the cost-effectiveness of preoperative chemo-sensitivity testing [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  4. Assess the predictive value of circulating tumour cells on disease-free survival [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  5. Assess the predictive value of SNPs on toxicity- and drug target-related genes on DFS [ Time Frame: Within 3 years after completion of adjuvant chemotherapy ]
  6. Create a frozen tumour bank for future studies [ Time Frame: Within 2 years from the beginning of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Clinical/radiological evaluation compatible with stage III colon adenocarcinoma
  • No prior chemotherapy
  • No prior abdominal or pelvic irradiation
  • WHO performance status 0 or 1
  • Effective contraception during the study and the following six months
  • Signed informed consent obtained prior to any study-specific screening procedures
  • Tumour considered as curatively resectable (R0) based on standard preoperative evaluations
  • White blood cell count ≥ 3×109/L with neutrophils ≥ 1.5×109/L, platelet count ≥ 100×109/L, haemoglobin ≥ 9 g/dL (5.6 mmol/L)
  • Direct bilirubin ≤ 1.5×ULN; ASAT and ALAT ≤ 2.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Serum creatinine ≤ 1.5×ULN
  • Delay between assessment of screening criteria and first PET/CT < 21 days
  • Blood glucose < 150 mg/dl at the time of FDG administration. Insulin or oral anti-diabetic medication is not allowed on the days of PET/CT imaging.
  • Compliance to the first chemotherapy course to be administered before surgery
  • Delay between the first PET/CT imaging and the start of neoadjuvant FOLOFX < 7 days
  • Second PET/CT imaging performed on D14 (range: D13-D15, with D1 as the first day of chemo administration)
  • Delay between the second PET/CT and surgery < 7 days
  • Stage III (ypTNM) as assessed after surgery
  • CEA < 1.5 x ULN 1 month after surgery -

Exclusion Criteria:

  • Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to screening. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
  • Any suspicion of metastatic disease
  • Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery
  • Inflammatory bowel disease
  • Pregnancy (absence to be confirmed by ß-hCG blood test) or breast-feeding
  • History or current central nervous system disease or peripheral neuropathy
  • Hypersensitivity to any of the components of study treatments
  • Previous malignancy in the last five years except basal-cell carcinoma of the skin or in situ cervical carcinoma
  • Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 weeks or high risk of uncontrolled arrhythmia
  • Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent
  • Any significant disease which, in the investigator's opinion, would exclude the patient from the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00994864

Show Show 21 study locations
Sponsors and Collaborators
Jules Bordet Institute
Layout table for investigator information
Principal Investigator: Alain Hendlisz, MD Jules Bordet Institute, Brussels, Belgium
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jules Bordet Institute
ClinicalTrials.gov Identifier: NCT00994864    
Other Study ID Numbers: PEPITA 001
EudraCT number: 2009-011445-13
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: November 29, 2018
Last Verified: November 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases